Hyperglycemia Clinical Trial
— NiPPeROfficial title:
Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health "(NiPPeR)"
Verified date | May 2023 |
Source | University of Southampton |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to assess whether a nutritional drink taken before conception and continuing through pregnancy, assists in the maintenance of healthy glucose metabolism in the mother and promotes offspring health.
Status | Completed |
Enrollment | 1729 |
Est. completion date | June 2022 |
Est. primary completion date | October 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 38 Years |
Eligibility | Inclusion Criteria: - Women aged 18-38 years - Planning to conceive within 6 months - Able to provide written, informed consent - In Singapore: Chinese, Malay and Indian ethnicity or mixed Chinese/Malay/Indian ethnicity Exclusion Criteria: - Pregnant or lactating at recruitment - Assisted fertility, apart from those taking clomiphene or letrozole alone - Pre-existing diabetes (type 1 or type 2) - Oral or implanted contraception currently or in the last month, or with an Intrauterine Contraceptive Device (IUCD) in situ - On metformin or systemic steroids currently or in the last month - Known serious food allergy - Not able to give informed consent - Women on anticonvulsants (who are treated with high dose B vitamins in pregnancy) currently or in the last month - On treatment for Human Immunodeficiency Virus (HIV), Hepatitis B or C currently or in the last month The partners of the women (over 16 years of age) will also be invited to participate in the study. After having gained written informed consent, fathers will have blood, urine, hair sampling, cheek swabs and body measurements taken and will complete a health and a lifestyle questionnaire at one of the visits during pregnancy. The mother will consent for their babies to have body measurements, buccal, hair, stool samples and allergy testing from birth to 3.5 years. |
Country | Name | City | State |
---|---|---|---|
New Zealand | The University of Auckland | Auckland | |
Singapore | National University Hospital | Singapore | |
United Kingdom | University Hospital Southampton NHS Foundation Trust | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Southampton | Auckland UniServices Ltd., National University Hospital, Singapore, National University of Singapore, Nestec Ltd., Singapore Institute for Clinical Sciences |
New Zealand, Singapore, United Kingdom,
Godfrey KM, Cutfield W, Chan SY, Baker PN, Chong YS; NiPPeR Study Group. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials. 2017 Mar 20;18(1):131. doi: 10.1186/s13063-017-1875-x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Health economics analysis (cost benefit analysis) | Composite analysis between preconception visit which is up to 1 year before pregnancy and infant age 3.5 years, assessed up to 5.5 years | ||
Other | Offspring neurocognitive and behavioural development (behavioural and Ages & Stages questionnaires) | Up to 3.5 years, from birth to infant age 3.5 years | ||
Other | Offspring respiratory development (absence of respiratory symptoms) | Up to 3.5 years, from birth to infant age 3.5 years | ||
Other | Offspring allergic development (clinical evaluation of atopic disorders and skin prick test reaction diameter) | Up to 3.5 years, from birth to infant age 3.5 years | ||
Other | Offspring health and wellbeing (questionnaires) | Up to 3.5 years, from birth to infant age 3.5 years | ||
Other | Maternal health and wellbeing | Up to 4 years, between preconception visit which is up to 1 year before pregnancy and up to 2 years after delivery | ||
Primary | Glucose tolerance during pregnancy | Pregnancy Oral Glucose Tolerance Test (OGTT) measurement at 24 - 32 weeks gestation | ||
Secondary | Duration of gestation | Up to 43 weeks, derived from estimated date of conception from menstrual and ultrasound scan data and date of delivery | ||
Secondary | Pregnancy weight gain and body composition | Up to 36 weeks, between date of first pregnancy visit and late gestation | ||
Secondary | Postpartum weight retention and body composition | Up to 2 years, between date of delivery and 6,12 and 24 months postpartum | ||
Secondary | Change in body composition before, during and after gestation | Up to 4 years, between preconception, pregnancy and 2 years postpartum | ||
Secondary | Clinical pregnancy, pregnancy loss and live birth rates, including median time to conception of those who conceive during the treatment period and proportions conceiving within 3 months, 6 months and a year of commencing the NiPPeR drink | Between recruitment and delivery | ||
Secondary | Gestational diabetes frequency | Pregnancy OGTT measurement at 24 - 32 weeks gestation | ||
Secondary | Hypertensive disorders of pregnancy (pregnancy-induced hypertension and pre-eclampsia/eclampsia) | Up to 49 weeks, between conception derived from estimated date of conception from menstrual and ultrasound scan data and date of delivery, and up to 6 weeks after delivery | ||
Secondary | Nausea and vomiting frequency | Up to 36 weeks, between 7 weeks of gestation and delivery | ||
Secondary | Other antenatal, perinatal and postnatal complications | Up to 49 weeks, between conception from estimated date of conception derived from menstrual and ultrasound scan data, and up to 6 weeks after delivery | ||
Secondary | Preconception and antenatal maternal wellbeing/mood (Edinburgh Post-natal Depression Scale and State-Trait Anxiety Inventory) | Up to 2 years, between preconception and delivery | ||
Secondary | Postnatal maternal wellbeing/mood (Edinburgh Post-natal Depression Scale and State-Trait Anxiety Inventory) | Up to 52 weeks, between date of delivery and infant age 1 year | ||
Secondary | Mode of labour onset and delivery | Delivery | ||
Secondary | Neonatal complications and admission to neonatal care facilities | Up to 4 weeks post-delivery | ||
Secondary | Preconception maternal micronutrient status (blood analysis) | Date of second preconception visit up to 1 year before pregnancy | ||
Secondary | Antenatal maternal micronutrient status (blood analysis) | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation | ||
Secondary | Preconception maternal gut microbiota composition and activity profile (analysis of sequencing and transcription data) | Up to 6 weeks from the start of intervention, date of preconception visit 2 which is up to 1 year before pregnancy | ||
Secondary | Antenatal and postnatal maternal gut and epithelial microbiota composition profile (analysis of sequencing data) | Up to 18 months, between 7 weeks gestation and post-delivery visits | ||
Secondary | Maternal preconception biochemical, metabolic and molecular profiles | Up to 6 weeks from the start of intervention, date of second preconception visit which is up to 1 year before pregnancy | ||
Secondary | Maternal antenatal biochemical, metabolic and molecular profiles | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation | ||
Secondary | Placental and cord tissue, and their cellular derivatives: biochemical, metabolic and molecular profiles | Birth | ||
Secondary | Maternal postnatal biochemical, metabolic and molecular profiles | 6 months after delivery | ||
Secondary | Maternal preconception epigenetic profile | Preconception to up to 1 year before pregnancy | ||
Secondary | Maternal antenatal epigenetic profile | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation | ||
Secondary | Maternal postnatal epigenetic profile | 6 months after delivery | ||
Secondary | Breast milk macronutrient profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Breast milk micronutrient profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Breast milk immune factor profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Breast milk epigenetic profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Breast milk biochemical, metabolic, microbiome and molecular profiles (subsample) | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Healthy lactogenesis | Up to 1 year, between date of delivery and 1 year postpartum | ||
Secondary | Maternal and infant transcriptomics (including of breastmilk) | Up to 34 months, between preconception, pregnancy and 1 year postpartum | ||
Secondary | Intrauterine growth and wellbeing as assessed by antenatal serial ultrasound scans | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation | ||
Secondary | Offspring birthweight and size at birth | At birth | ||
Secondary | Offspring size for gestational age at birth, less than the 10th, 10th - 90th, and above the 90th percentiles for gestational age | At birth | ||
Secondary | Offspring size for gestational age and sex at birth (percentile and standard deviation scores) | At birth | ||
Secondary | Offspring adiposity (skinfold thicknesses, regional, total and percentage fat mass) | Up to 3.5 years, between date of delivery and 3.5 years postpartum | ||
Secondary | Adiposity gain, body composition and linear growth during infancy and childhood | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Cord blood C-peptide | At delivery | ||
Secondary | Offspring cardiometabolic profile | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Offspring allergic wellbeing | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Offspring biochemical, metabolic and molecular profiles | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Offspring epigenetic profile | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Infant gut microbiota composition and activity | Up to 3.5 years, from birth to infant age 3.5 years | ||
Secondary | Influence of parental and offspring genotype, sociodemography, body composition, metabolism, lifestyle and diet on the above primary and secondary outcomes at baseline and with the intervention | Up to 5.5 years, between preconception, pregnancy and 3.5 years postpartum |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01267448 -
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
|
Phase 4 | |
Recruiting |
NCT03775733 -
Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia
|
N/A | |
Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Completed |
NCT00535600 -
Effects of Bariatric Surgery on Insulin
|
||
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Recruiting |
NCT02885922 -
The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
|
||
Recruiting |
NCT02885909 -
Inpatient Blood Glucose Control in Taichung Veterans General Hospital
|
Phase 4 | |
Completed |
NCT02012465 -
Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients
|
Early Phase 1 | |
Withdrawn |
NCT01488383 -
Effect of Stevioside in Postpandrial Glucose in Healthy Adults
|
N/A | |
Completed |
NCT01805414 -
Breakfast Nutrition and Inpatient Glycemia
|
N/A | |
Completed |
NCT01803568 -
Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU
|
N/A | |
Completed |
NCT01810952 -
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
|
Phase 4 | |
Active, not recruiting |
NCT01247714 -
Clinical Evaluation of a Specific Enteral Diet for Diabetics
|
N/A | |
Not yet recruiting |
NCT00846144 -
The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients
|
N/A | |
Completed |
NCT00996099 -
Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients
|
N/A | |
Recruiting |
NCT00654797 -
Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2
|
Phase 2 | |
Completed |
NCT00468494 -
Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?
|
N/A | |
Completed |
NCT00394407 -
Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes
|
Phase 4 |